# Iomeprol

Source: https://onco.cc/drugs/iomeprol/  
OnCo record `iomeprol` (Imaging agent). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A CT and angiography dye approved in the United States in 2024.

## Summary

Bracco's Iomervu (NDA 216016, first approved 27 November 2024) is indicated for intra-arterial procedures and intravenous procedures including "Computed tomography (CT) of the head and body in adults and pediatric patients", CT angiography, coronary CT angiography and CT urography. ATC V08AB10.

## Fields

- Kind: Imaging agent
- Status: approved
- Last checked: 2026-11-04
- Also known as: iomeprol; Iomervu
- Tags: contrast-agents-gaps-2026-11; diagnostic
- Brand: Iomervu
- Modality: Iodinated contrast agent for CT and angiography (intravenous, intra-arterial)
- Mechanism: A non-ionic low-osmolar iodinated molecule that makes vessels and enhancing tissues appear bright on CT and X-ray.
- Approvals: US 2024: Angiography; CT of the head and body; CT angiography; CT urography

## Sources

- Drugs@FDA Iomervu (NDA 216016): https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216016
- DailyMed label: Iomervu: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb2e0e00-7c93-0fb4-89a5-861641662a5a
- WHO ATC index V08AB: low osmolar X-ray contrast media: https://atcddd.fhi.no/atc_ddd_index/?code=V08AB&showdescription=no

## Connected records

- technologies: [CT (computed tomography)](https://onco.cc/technologies/ct/), [Iodinated and barium contrast for CT and X-ray](https://onco.cc/technologies/iodinated-contrast-media/)
- companies: [Bracco (Bracco Imaging and Bracco Diagnostics)](https://onco.cc/companies/bracco/)

---
JSON: https://onco.cc/api/v1/entities/iomeprol.json